1. Introduction {#sec1-cancers-12-00471}
===============

The transcription growth factor β (TGF-β) signaling pathway has been studied extensively in several cancer types, including breast cancer (BC). The TGF-β superfamily consists of 33 structurally similar members, including bone morphogenic proteins (BMPs), TGF-β ligands, and activins, which play important roles in mammary development \[[@B1-cancers-12-00471],[@B2-cancers-12-00471],[@B3-cancers-12-00471]\]. In humans, isoforms of TGF-β ligands that are closely related both structurally and functionally (TGF-β1, TGF-β2, and TGF-β3) have been reported to modulate cell progression, migration, and apoptosis \[[@B4-cancers-12-00471]\]. During cancer development, TGF-β exhibits both tumorigenic and tumor-suppressive roles \[[@B5-cancers-12-00471]\]. It has been reported that, whereas TGF-β acts as a tumor suppressor during the early stages of cancer development, it exhibits oncogenic properties, inducing cell migration and invasion, during the later stages \[[@B2-cancers-12-00471],[@B6-cancers-12-00471],[@B7-cancers-12-00471]\].

Several polymorphisms have been identified in the *TGF-β1* gene (*TGFβ1*), including two located in exon 1 (*TGF-β1* 29T\>C and *TGF-β1\*6A*) and two located in the promoter region (*TGF-β1*-509 C/T and *TGF-β1*-800 G/A) \[[@B8-cancers-12-00471],[@B9-cancers-12-00471],[@B10-cancers-12-00471]\]. There is increasing evidence of an association between these polymorphisms and elevated cancer risk \[[@B11-cancers-12-00471]\]. Researchers demonstrated that the *TGF-β1* 29T\>C polymorphism increases the secretion of TGF-β levels \[[@B9-cancers-12-00471]\]. Ziv et al. demonstrated that CC genotype of the *TGF-β1* 29T\>C polymorphism decreases BC risk by up to 64% among Whites \[[@B12-cancers-12-00471]\]. In contrast, Dunning et al. found that this polymorphism was associated with an increased risk of BC \[[@B9-cancers-12-00471]\]. In a multi-ethnic cohort study, there was no association between this polymorphism and BC risk in postmenopausal Caucasian women \[[@B13-cancers-12-00471]\]. However, a meta-analysis of case--control studies established a moderate association between the *TGF-β1* 29T\>C polymorphism and BC susceptibility \[[@B14-cancers-12-00471]\], and it included studies that either did not assess BC risk, lacked information regarding control samples, or did not incorporate data from more recent studies that might influence the combined ORs. Our present meta-analysis rectifies these previous mistakes by excluding studies that did not assess BC risk and/or did not have information regarding control samples.

The *TGF-β1*-509 C/T polymorphism, which is present in the promoter region of *TGF-β1,* influences its expression \[[@B15-cancers-12-00471],[@B16-cancers-12-00471]\]. Elevated levels of *TGF-β1* in plasma were associated with the T allele of *TGF-β1*-509 C/T \[[@B16-cancers-12-00471]\]. Several studies have assessed the association between *TGF-β1*-509 C/T polymorphism and BC risk \[[@B17-cancers-12-00471]\]. This polymorphism has also been associated with radiation-induced fibrosis; however, contrasting results have also been recently obtained \[[@B18-cancers-12-00471]\].

The deletion of three alanine residues within the nine-alanine repeat sequence (\* 9A) of the *TGF*-*β* exon 1 region results in the formation of the *TGF-β1\*6A* variant \[[@B10-cancers-12-00471]\]. Studies have suggested that the *TGF-β1\*6A* variant exhibits significantly fewer tumor-suppressive properties than wild-type *TGF-β1* \[[@B19-cancers-12-00471]\]. *TGF-β1\*6A* is a tumor-susceptibility allele that is highly correlated with the risk of various cancer types \[[@B20-cancers-12-00471]\]. Baxter et al. found that the *TGF-β1\*6A* variant increased BC risk by 60% \[[@B21-cancers-12-00471]\]. However, contradictory results have also been observed \[[@B19-cancers-12-00471],[@B22-cancers-12-00471],[@B23-cancers-12-00471],[@B24-cancers-12-00471],[@B25-cancers-12-00471]\]. Therefore, we performed the current meta-analysis to provide conclusive evidence for the associations between *TGF-β1* polymorphisms and BC risk.

2. Results {#sec2-cancers-12-00471}
==========

2.1. Characteristics of Studies Included in the Meta-Analysis {#sec2dot1-cancers-12-00471}
-------------------------------------------------------------

Initially, 3043 hits were obtained from publications on PubMed, EMBASE, and Google Scholar. Among them, 373 publications were reviews, which were excluded. The remaining studies were retrieved, scrutinized, and evaluated by reading their titles and abstracts. Eighty potentially eligible studies were retrieved as full texts, 39 of which were eligible for inclusion in the meta-analysis. Precisely, 23 studies \[[@B9-cancers-12-00471],[@B12-cancers-12-00471],[@B13-cancers-12-00471],[@B26-cancers-12-00471],[@B27-cancers-12-00471],[@B28-cancers-12-00471],[@B29-cancers-12-00471],[@B30-cancers-12-00471],[@B31-cancers-12-00471],[@B32-cancers-12-00471],[@B33-cancers-12-00471],[@B34-cancers-12-00471],[@B35-cancers-12-00471],[@B36-cancers-12-00471],[@B37-cancers-12-00471],[@B38-cancers-12-00471],[@B39-cancers-12-00471],[@B40-cancers-12-00471],[@B41-cancers-12-00471],[@B42-cancers-12-00471],[@B43-cancers-12-00471],[@B44-cancers-12-00471],[@B45-cancers-12-00471]\] covered the *TGF-β1* 29T\>C polymorphism (also known as Pro10Leu, T869C, rs1982073, and rs1800470), whereas 13 studies \[[@B9-cancers-12-00471],[@B28-cancers-12-00471],[@B29-cancers-12-00471],[@B30-cancers-12-00471],[@B35-cancers-12-00471],[@B40-cancers-12-00471],[@B46-cancers-12-00471],[@B47-cancers-12-00471],[@B48-cancers-12-00471],[@B49-cancers-12-00471],[@B50-cancers-12-00471],[@B51-cancers-12-00471],[@B52-cancers-12-00471]\] covered the *TGF-β1*-509 C/T polymorphism (also known as −1349C\>T and rs1800469), and 13 studies \[[@B9-cancers-12-00471],[@B21-cancers-12-00471],[@B28-cancers-12-00471],[@B31-cancers-12-00471],[@B33-cancers-12-00471],[@B35-cancers-12-00471],[@B39-cancers-12-00471],[@B47-cancers-12-00471],[@B53-cancers-12-00471],[@B54-cancers-12-00471],[@B55-cancers-12-00471],[@B56-cancers-12-00471],[@B57-cancers-12-00471]\] covered the *TGF-β1\*6A* polymorphism. Genotypic and allelic frequencies from each eligible case-control study were extracted. The characteristics of all eligible studies are represented in [Table 1](#cancers-12-00471-t001){ref-type="table"}. Studies were sub-categorized based on the ethnicities of the individuals studied (Caucasian, European, Middle Eastern, and Asian), and were analyzed separately. [Supplementary Figure S1](#app1-cancers-12-00471){ref-type="app"} depicts the selection of studies in a comprehensive PRISMA flow chart.

2.2. Assessment of Heterogeneity among the Studies and Publication Bias {#sec2dot2-cancers-12-00471}
-----------------------------------------------------------------------

Heterogeneity was observed in the allelic models of all three *TGF-β1* polymorphisms, as well as all genetic models of the *TGF-β1* 29T\>C polymorphism and the homozygous model of the *TGF-β1*-509 C/T polymorphism. In contrast, none of the genetic models of the *TGF-β1\*6A* polymorphism were heterogeneous. Heterogeneity among the studies of all three polymorphisms in all ethnic groups is represented in [Supplementary Table S1](#app1-cancers-12-00471){ref-type="app"}. Information regarding the presence of potential publication bias in ethnic studies is illustrated in [Supplementary Figure S2](#app1-cancers-12-00471){ref-type="app"}.

2.3. TGF-β1 29T\>C, or T869C, Polymorphism {#sec2dot3-cancers-12-00471}
------------------------------------------

Data from 23 eligible case--control studies were extracted to evaluate the association between the *TGF-β1* 29T\>C polymorphism and BC risk. Interestingly, neither the overall allele model nor any of the genetic models showed a significant association between the *TGF-β1* 29T\>C polymorphism with increased risk of BC (Combined analysis: overall allele (OR) = 1.026, 95% confidence interval (CI) = 0.946--1.114, *p* = 0.536; homozygous: OR = 1.063, 95% CI = 0.890--1.270, *p* = 0.500; heterozygous: OR = 1.048, 95% CI = 0.912--1.204, *p* = 0.508; recessive: OR = 1.040, 95% CI = 0.950--1.140, *p* = 0.396; dominant: OR = 1.056, 95% CI = 0.922--1.209, *p* = 0.430) ([Figure 1](#cancers-12-00471-f001){ref-type="fig"} and [Figure 2](#cancers-12-00471-f002){ref-type="fig"}).

2.4. TGF-β1-509 C/T, or -1349C\>T, Polymorphism {#sec2dot4-cancers-12-00471}
-----------------------------------------------

Data from 13 eligible case--control studies were extracted to evaluate the association between the *TGF-β1*-509 C/T polymorphism and BC risk. None of the models showed a significant association between the *TGF-β1*-509 C/T polymorphism and BC risk (Combined analysis: overall allele (OR)  =  0.986, 95% CI = 0.923--1.053, *p* = 0.676; homozygous: OR = 0.971, 95% CI = 0.836--1.127, *p* = 0.696; heterozygous: OR = 0.986, 95% CI = 0.936--1.039, *p* = 0.594; recessive: OR = 0.985, 95% CI = 0.912--1.064, *p* = 0.706; dominant: OR = 0.984, 95% CI = 0.937--1.034, *p* = 0.527) ([Figure 3](#cancers-12-00471-f003){ref-type="fig"}).

2.5. TGF-β1\*6A polymorphism {#sec2dot5-cancers-12-00471}
----------------------------

Data from 13 eligible case--control studies were extracted to evaluate the association between the *TGF-β1\*6A* polymorphism and BC risk. Again, none of the models showed a significant association between the *TGF-β1\*6A* polymorphism and BC (Combined analysis: overall allele (OR)  =  1.123, 95% CI = 0.967--1.305, *p* = 0.129; homozygous: OR = 1.051, 95% CI = 0.726--1.521, *p* = 0.793; heterozygous: OR = 1.097, 95% CI = 0.996--1.208, *p* = 0.060; recessive: OR = 1.051, 95% CI = 0.726--1.520, *p* = 0.794; dominant: OR = 1.081, 95% CI = 0.989--1.182, *p* = 0.087) ([Figure 4](#cancers-12-00471-f004){ref-type="fig"}). These results for each polymorphism did not differ by genotyping method ([Supplementary Figures S3 and S4](#app1-cancers-12-00471){ref-type="app"}).

2.6. Stratified Analysis {#sec2dot6-cancers-12-00471}
------------------------

Studies were categorized based on the ethnicities of the individuals studied. Studies covering the *TGF-β1* 29T\>C polymorphisms were divided into four groups: Caucasian, European, Asian, and Middle Eastern. The *TGF-β1* 29T\>C polymorphism was found to be associated with BC risk in the heterozygous model of the Asian population (OR = 1.115, 95% CI = 1.006--1.237, *p* = 0.039). In contrast, the same polymorphism was associated with lower odds of BC in the heterozygous model of the Middle Eastern population (OR = 0.602, 95% CI = 0.375--0.966, *p* = 0.035) ([Figure 5](#cancers-12-00471-f005){ref-type="fig"}). No correlation was found between the *TGF-β1* 29T\>C polymorphism and BC risk in the Caucasian and European populations. Similarly, results of other variants of *TGF-β1* polymorphism have shown no association with BC risk in ethnic groups. These findings suggested that the *TGF-β1* 29T\>C polymorphism alone is associated with BC risk in the Asian population. The ORs and 95% CIs of all stratified ethnic group analyses are provided in [Table 2](#cancers-12-00471-t002){ref-type="table"}.

2.7. Sensitivity Analysis {#sec2dot7-cancers-12-00471}
-------------------------

One-way sensitivity analysis was performed to analyze the effect of each study on the combined OR. During the sensitivity analysis for each polymorphism, each relevant study was deleted iteratively from the dataset prior to the analysis. No single study had a significant influence on any of the combined ORs, suggesting that our meta-analysis is relatively robust and credible ([Supplementary Figures S5--S7](#app1-cancers-12-00471){ref-type="app"}).

2.8. Trial Sequential Analysis (TSA) {#sec2dot8-cancers-12-00471}
------------------------------------

TSA was used to investigate whether the number of samples included in the present study was sufficient for detecting a possible role of each *TGF-β1* polymorphism in BC. The Z curve touched the trial monitoring boundaries or reached the required information line, indicating that a sufficient number of studies were included in the meta-analysis for overall and ethnic group investigations ([Supplementary Figure S8](#app1-cancers-12-00471){ref-type="app"}).

3. Discussion {#sec3-cancers-12-00471}
=============

The *TGF-β1* signaling pathway has been studied extensively in several cancers, including BC. *TGF-β1* plays an important role in cell differentiation, migration, invasion, and tumor growth \[[@B4-cancers-12-00471]\]. Both tumorigenic and tumor-suppressive roles of *TGF-β1* have been well established \[[@B5-cancers-12-00471]\]. Elevated plasma levels of *TGF-β1* have been associated with cancer development, and *TGF-β1* polymorphisms have been found to cause high transcription and expression of *TGF-β1* \[[@B9-cancers-12-00471],[@B11-cancers-12-00471]\]. The prominent role of *TGF-β1* in cancer progression underscores the importance of studying the association between *TGF-β1* polymorphisms and BC risk.

The most common *TGF-β1* polymorphism is a substitution of cytosine with thymine at the 29th nucleotide (*TGF-β1* 29 T\>C), which results in the substitution of the proline at codon 10 in exon 1 with leucine \[[@B8-cancers-12-00471],[@B9-cancers-12-00471],[@B10-cancers-12-00471],[@B11-cancers-12-00471]\]. *TGF-β1* 29T\>C has been associated with elevated levels of *TGF-β1* in plasma \[[@B9-cancers-12-00471]\]. Studies have also suggested that *TGF-β1* 29T\>C is associated with BC risk; however, contrasting results were reported. Dunning et al. suggested that the *TGF-β1* 29T\>C polymorphism is associated with BC risk; they also found that this polymorphism is associated with elevated levels of the *TGF-β1* protein \[[@B9-cancers-12-00471]\]. In contrast, Ziv et al. reported no such associations \[[@B12-cancers-12-00471]\]. Marchand et al. reported similar results in their multi-ethnic study, which suggested no association between the *TGF-β1* 29T\>C polymorphism and BC \[[@B13-cancers-12-00471]\]. Interestingly, Lee et al. demonstrated that the *TGF-β1* 29T\>C polymorphism was associated with an increased risk of BC in postmenopausal women \[[@B32-cancers-12-00471],[@B33-cancers-12-00471]\]. However, Hishida et al. observed a negative correlation between the *TGF-β1* 29T\>C polymorphism and BC risk in premenopausal women \[[@B27-cancers-12-00471]\]. Interestingly, Shin et al. demonstrated that no association was found in the initial stages of BC, whereas a significant correlation was observed in later stages \[[@B30-cancers-12-00471]\].

A systematic meta-analysis was performed to provide conclusive evidence for the association of TGF-β polymorphism with breast cancer risk. Interestingly, neither the overall allele nor genotypic models showed an association between the *TGF-β1* 29T\>C polymorphism and BC risk. However, the *TGF-β1* 29T\>C polymorphism was found to be associated with an increased risk of BC in the heterozygous model of the Asian population. In contrast, the *TGF-β1*29T\>C polymorphism favors lower odds of BC in the heterozygous model of the Middle Eastern population.

The *TGF-β1*-509 C/T polymorphism is located in the promoter region of *TGF-β1*. Recent studies demonstrated the association between the *TGF-β1*-509 C/T polymorphism and elevated levels of the TGF-β protein. It has also been well established that the *TGF-β1*-509 C/T polymorphism is highly associated with BC risk. Both Dunning et al. \[[@B9-cancers-12-00471]\] and Parvizi et al. \[[@B52-cancers-12-00471]\] suggested that the polymorphism is associated with increased risk of invasive BC, whereas Cox et al. showed no such association \[[@B35-cancers-12-00471]\]. Vinod et al. demonstrated that heterozygosity of the *TGF-β1*-509 C/T polymorphism was associated with BC susceptibility in an Indian population \[[@B51-cancers-12-00471]\]. However, Babyshkina et al. reported that homozygosity of the T allele of the *TGF-β1*-509 C/T polymorphism was not associated with BC in a Russian population \[[@B49-cancers-12-00471]\]. These inconclusive and controversial results suggest the necessity of a cumulative and robust analysis to arrive at a definitive conclusion regarding the association between this polymorphism and cancer risk in multiple ethnic groups. Six meta-analyses were performed to address these issues; three investigated the association between the *TGF-β1*-509 C/T polymorphism and multiple cancer subtypes. Huang et al., Qi et al., and Woo et al. performed meta-analyses examining the association between the *TGF-β1*-509 C/T polymorphism and BC specifically \[[@B14-cancers-12-00471],[@B17-cancers-12-00471],[@B58-cancers-12-00471]\]. However, these studies were performed using a limited number of studies, and Huang et al. included a study that was not related to BC risk \[[@B58-cancers-12-00471]\]. These drawbacks can influence the analysis and affect the results. In order to definitively determine the association between the *TGF-β1*-509 C/T polymorphism and BC, we performed a meta-analysis including additional studies and excluding studies not related to BC risk. Our robust analysis demonstrated that the *TGF-β1*-509 C/T polymorphism is not associated with BC in the overall population or within specific ethnic groups.

Researchers have identified a polyalanine variant in exon 5 of *TGF-β1* and analyzed its association with BC risk. Recent studies have also suggested that the *TGF-β1\*6A* polymorphism is associated with BC risk. Specifically, Kaklamani et al., Pasche et al., and Song et al. reported that the polymorphism is associated with an increased incidence of BC \[[@B19-cancers-12-00471],[@B31-cancers-12-00471],[@B55-cancers-12-00471]\]. Pasche et al. also found that the *TGF-β1\*6A* polymorphism is associated with risk for other cancers, including colorectal and ovarian cancer \[[@B19-cancers-12-00471]\]. However, Chen et al., Colleran et al., and Cox et al. suggested that the *TGF-β1\*6A* variant is not associated with BC risk. Meta-analyses have been performed; however, they investigated the association between the *TGF-β1\*6A* polymorphism and all cancer types; no meta-analyses have yet correlated this polymorphism with BC specifically \[[@B20-cancers-12-00471],[@B59-cancers-12-00471]\]. Thus, in the present study, we analyzed for the first time the association between the *TGF-β1\*6A* polymorphism and BC risk. Our cumulative analysis suggests that the *TGF-β1\*6A* variant is not associated with BC risk. In our analysis of the European ethnic group, the *TGF-β1\*6A* variant also showed no association with BC risk.

Although various meta-analyses have already been reported in the literature, the present study has several advantages over them. A recent investigation by Alqumber et al. included reports published until the year 2013; in contrast, we screened for studies published up to May 2019, resulting in the inclusion of three additional studies. Furthermore, we assessed the possible association of three *TGF-β1* polymorphisms (*TGF-β1* 29\>T/C, *TGF-β1*-509 C/T, and *TGF-β1*\*6A) with the risk of BC \[[@B60-cancers-12-00471]\]. However, multiple comparisons failed to show a significant correlation between these polymorphisms with BC risk: the present study warrants the non-importance of TGF-β1 polymorphisms on the pathogenesis of BC. Finally, TSA revealed that our meta-analysis included a sufficient number of studies, performed worldwide, to dissect the possible association of *TGF-β1* variants with BC risk, and further investigation is not required.

4. Materials and Methods {#sec4-cancers-12-00471}
========================

4.1. Literature Search Strategy and Selection of Relevant Studies {#sec4dot1-cancers-12-00471}
-----------------------------------------------------------------

Three researchers independently conducted a comprehensive systematic electronic literature search using the online databases Pubmed, EMBASE, and Google Scholar. The following terms were used either alone or in combination: "Transforming Growth Factor β1 polymorphism"; "breast cancer"; for the *TGF-β1* 29T\>C polymorphism: "*TGF-β1* 29T\>C", "*TGF-β1*Pro10Leu", "*TGF-β1*T869C", "rs1982073", "rs180047029"; for the *TGF-β1*-509 C/T polymorphism: "*TGF-β1*-509 C/T", "*TGF-β1* 1349C\>T", "rs1800469"; and for the *TGF-β1\*6A* polymorphism: "*TGF-β1\*6A*", "rs11466445". We also examined the cross-references in the retrieved studies for publications that were missed in the above search.

4.2. Criteria for the Inclusion and Exclusion of Studies {#sec4dot2-cancers-12-00471}
--------------------------------------------------------

The present meta-analysis included studies that evaluated the association between *TGF-β1* polymorphisms and BC risk, were published in English, presented original data, and provided the genotypic frequency of both case and control samples or had odds ratios (ORs) with 95% confidence interval (CI) values. The analysis excluded reviews, abstracts, duplicate or overlapping studies, studies not published in English, studies that correlated *TGF-β1* polymorphisms with non-breast cancers, and studies that did not provide genotypic or allele frequencies for both case and control samples.

4.3. Data Extraction {#sec4dot3-cancers-12-00471}
--------------------

Each publication was assessed thoroughly, and data were extracted independently by three researchers, following the same pattern and extracting the same data essential for meta-analyses that have been previously described \[[@B22-cancers-12-00471],[@B23-cancers-12-00471]\]. The researchers conducted group discussions to resolve any discrepancies in extraction.

4.4. Statistical Analysis {#sec4dot4-cancers-12-00471}
-------------------------

Statistical analysis was performed using Comprehensive Meta-Analysis Software (CMA version 3) (Biostat, 14 North Dean Street, Englewood, NJ 07631 USA). In order to appraise the associations between *TGF-β1* polymorphisms and BC risk, the combined OR, 95% CIs, and their respective *p*-values were calculated by comparing the cancer patient samples vs. respective healthy controls. Heterogeneity among the studies and publication bias were calculated using Begg's funnel plots and chi-squared-based Cochran's Q tests, respectively. Egger's regression tests were performed to analyze and measure the symmetry of funnel plots, as described previously \[[@B22-cancers-12-00471]\]. Asymmetrical funnel plots were made symmetrical using the "Trim and Fill" method. Random models were used to calculate the combined ORs for studies showing heterogeneity \[[@B24-cancers-12-00471]\]. In contrast, fixed models were used to calculate the combined ORs for studies with homogeneity \[[@B25-cancers-12-00471]\].

4.5. Trial Sequential Analysis (TSA) {#sec4dot5-cancers-12-00471}
------------------------------------

An appropriate meta-analysis must include all eligible studies published to date to draw definitive conclusions. The number of studies available in the literature in the studied areas should be sufficient for decisive concluding remarks. TSA is a statistical tool developed by the Copenhagen Trial Unit, Centre for Clinical Intervention Research, Denmark, to estimate the sample size required to reach significance with definitive power. In TSA, a Z curve analysis is performed to check whether a sufficient number of samples is included in the study. If the Z curve intersects the TSA monitoring boundary before reaching the required information size or if the total number of samples exceeds the required information line, then the total number of studies included in the investigation is sufficient, and additional trials are not required. On the other hand, if the Z curve fails to touch the TSA monitoring boundaries or cross the required information line, the number of studies is limited and more are required to draw any definitive conclusions. TSA software version 0.9 (<http://www.ctu.dk/tsa>) was used for this analysis.

5. Conclusions {#sec5-cancers-12-00471}
==============

TGF-β1 plays an important role in BC progression, metastasis, stemness, and chemo-resistance. TGF-β1 has both pro-oncogenic and tumor-suppressive roles during cancer development. High levels of TGF-β1, which are influenced by *TGF-β1* polymorphisms, have been associated with cancer risk. *TGF-β1*polymorphisms have been associated with BC risk, but conflicting results have also been reported recently. Previous meta-analyses either included studies on *TGF-β1* polymorphisms that did not evaluate associations with BC or did not include new studies with huge datasets that could greatly influence their results. To address these shortcomings, a stringent and highly robust analysis was conducted to provide conclusive evidence for the association between *TGF-β1* polymorphisms and BC risk. The current meta-analysis included large datasets from all recent eligible studies and excluded studies that did not evaluate the associations between these polymorphisms and BC. This study suggests that *TGF-β1* polymorphisms are not associated with BC risk in the overall population. Both *TGF-β1*-509 C/T and *TGF-β1*\*6A also showed no association with BC risk in stratified analyses. However, the *TGF-β1* 29T\>C polymorphism was found to be associated with BC risk in the Asian ethnic group.
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The following are available online at <https://www.mdpi.com/2072-6694/12/2/471/s1>, Figure S1: PRISMA flowchart: Search, screening and selection of eligible studies included in meta-analysis for evaluating the association of TGF-β polymorphisms with breast cancer risk. Figure S2: Funnel plot: Assessment of publication bias using Begg's funnel plot and Egger's regression test. Asymmetric Begg's funnel plot was made symmetric using "Trim and Fill" method. Figure S3: Forest plot: Analyzing the influence of detection methods on association of TGF-β1 29T\>C polymorphism with breast cancer risk. Studies were separated based on the methods used for the detection of polymorphism \[(A) PCR-RFLP and (B) Taqman\] and were analyzed individually. Figure S4: Forest plot: Studies were separated based on the methods used for the detection of TGF-β1 -509 C/T polymorphism \[(A) PCR-RFLP and (B) Taqman\] and were analyzed individually to assess its association with increased risk of breast cancer. Figure S5: Sensitivity analysis: One individual study of TGF-β1 29T\>C was excluded each time and was analyzed to assess the effect of individual study on combined OR. Figure S6: Sensitivity analysis: Each study was assessed for the potential influence on combined OR by deleting single study each time and performing the analysis for TGF-β1 -509 C/T polymorphism. Figure S7: Sensitivity analysis of each study representing TGF-β \*6A polymorphism in the meta-analysis by one study removal method. Figure S8: Trial sequence analysis of all the included studies. TSA figure for TGFβ-1 29T\>C overall (A), Caucasian (B), Asian (C) showed enough number of samples enrolled for the analysis except for the American (D). TSA analysis for other two SNPs TGF-β1 -509 C/T (E) and TGF-β\*6A (F) also revealed similar results. Table S1: Statistics for heterogeneity test.
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![Forest plot of overall allele, homozygous, and heterozygous genotypic analyses of the *TGF-β1* 29T\>C polymorphism and assessment of its association with BC risk using combined odds ratios (ORs) and 95% confidence intervals (CIs) of the ORs. Black squares represent the ORs of the individual studies, and horizontal lines indicate the 95% CIs of the ORs.](cancers-12-00471-g001){#cancers-12-00471-f001}
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###### 

Characteristics of all studies included for meta-analysis.

  ---------------------------------------------------------------- ------------------------------------------------------- ------------------- ------------------- ------------------- ------------- --------------------------- ----------------------------- ----------------------- ----------- ----------------------------- ----------- ----------------------- -------------- -------------- -------------- ----------------------------
  **S.No.**                                                        **First Author**                                        **Year**            **Ethnicity**       **Case**            **Control**   **Genotype Distribution**                                                                     **Allele Distribution (%)**               **Genotyping method**                                                
  **TGFβ1 29C\>T (Pro10Leu) or T869C or rs1982073 or rs1800470**   **Breast cancer**                                                           **Control**                                           **Breast Cancer**           **Control**                                                                                                                                                                      
                                                                                                                                                                                                     **TT**                      **TC**                        **CC**                  **TT**      **TC**                        **CC**      **T**                   **C**          **T**          **C**          
  1                                                                Ziv et al \[[@B12-cancers-12-00471]\]                   2001                Caucasian           146                 2929          56                          80                            10                      1068        1413                          448         192 (65.75)             100 (34.25)    3549 (60.58)   2309 (39.42)   PCR-RFLP
  2                                                                Krippl et al \[[@B26-cancers-12-00471]\]                2003                Caucasian           495                 499           196                         219                           80                      182         229                           88          611 (61.71)             379 (38.29)    593 (59.42)    405 (40.58)    PCR
  3                                                                Dunning et al ^a^ \[[@B9-cancers-12-00471]\]            2003                UK                  1,752               1877          99                          1228                          425                     735         889                           253         1426 (40.7)             2078 (59.3)    2359 (62.84)   1395 (37.16)   Taqman
  4                                                                Dunning et al ^b^ \[[@B9-cancers-12-00471]\]            2003                European            415                 574           116                         220                           79                      202         274                           98          452 (54.45)             378 (45.54)    678 (59.06)    470 (40.94)    Taqman
  5                                                                Dunning et al ^c^ \[[@B9-cancers-12-00471]\]            2003                Finnland            481                 451           255                         191                           35                      232         191                           28          701 (72.90)             261 (27.1)     655 (72.62)    247 (27.38)    Taqman
  6                                                                Hishida et al \[[@B27-cancers-12-00471]\]               2003                Asian               232                 177           67                          107                           58                      42          87                            48          241 (51.9)              223 (48.1)     171 (48.30)    183 (51.7)     PCR-CTPP
  7                                                                Marchand et al ^a^ \[[@B13-cancers-12-00471]\]          2004                Afro-American       233                 612           76                          112                           45                      205         289                           118         264 (56.65)             202 (43.35)    699 (57.11)    525 (42.89)    Taqman
  8                                                                Marchand et al ^b^ \[[@B13-cancers-12-00471]\]          2004                Latina              225                 647           67                          111                           47                      179         308                           160         245 (54.44)             205 (45.56)    666 (51.47)    628 (48.53)    Taqman
  9                                                                Marchand et al ^c^ \[[@B13-cancers-12-00471]\]          2004                White               299                 402           114                         137                           48                      141         183                           78          365 (61.0)              233 (39)       465 (57.84)    339 (42.16)    Taqman
  10                                                               Marchand et al ^d^ \[[@B13-cancers-12-00471]\]          2004                Japanese            303                 385           62                          163                           78                      91          183                           111         287 (47.36)             319 (52.64)    365 (47.40)    405 (52.6)     Taqman
  11                                                               Marchand et al ^e^ \[[@B13-cancers-12-00471]\]          2004                Hawaiian            63                  268           19                          27                            17                      74          140                           54          65 (51.6)               61 (48.4)      288 (53.73)    248 (46.27)    Taqman
  12                                                               jin et al ^a^ \[[@B28-cancers-12-00471]\]               2004                Finnland            223                 234           119                         93                            11                      123         91                            20          331 (74.2)              115 (25.8)     337 (72.0)     131 (28.0)     PCR-RFLP, PCR-ALF
  13                                                               jin et al ^b^ \[[@B28-cancers-12-00471]\]               2004                Polish              415                 205           151                         189                           75                      66          105                           34          491 (59.15)             339 (40.85)    237 (57.8)     173 (42.2)     PCR-RFLP, PCR-ALF
  14                                                               jin et al ^c^ \[[@B28-cancers-12-00471]\]               2004                German              160                 162           63                          72                            25                      46          96                            20          198 (61.87)             122 (38.13)    188 (58.02)    136 (41.98)    PCR-RFLP, PCR-ALF
  15                                                               jin et al ^d^ \[[@B28-cancers-12-00471]\]               2004                Swedish             84                  173           31                          38                            15                      70          77                            26          100 (59.5)              68 (40.5)      217 (62.72)    129 (37.28)    PCR-RFLP, PCR-ALF
  16                                                               Saha et al \[[@B29-cancers-12-00471]\]                  2004                Asian               23                  84            10                          13                            0                       47          33                            4           33 (71.7)               13 (28.3)      127 (75.6)     41 (24.4)      PCR-SSCP
  17                                                               Shin et al \[[@B30-cancers-12-00471]\]                  2005                Asian               1,114               1189          258                         554                           302                     255         615                           319         1070 (48.1)             1158 (51.9)    1125 (47.31)   1253 (52.69)   PCR-RFLP
  18                                                               Kaklamani et al \[[@B31-cancers-12-00471]\]             2005                Caucasian           658                 841           200                         339                           119                     240         419                           182         739 (56.1)              577 (43.9)     899 (53.45)    783 (46.55)    PCR-seq
  19                                                               Lee et al \[[@B32-cancers-12-00471]\]                   2005                Asian               558                 501           135                         288                           135                     148         235                           118         558 (50)                558 (50)       531 (53.0)     471 (47.0)     PCR-CTPP
  20                                                               Feigelson et al \[[@B33-cancers-12-00471]\]             2006                Caucasian           485                 481           182                         233                           70                      181         221                           79          597 (61.55)             373 (38.45)    583 (60.60)    379 (39.40)    Taqman
  21                                                               Scola et al \[[@B34-cancers-12-00471]\]                 2006                Caucasian           84                  106           41                          27                            16                      35          52                            19          109 (64.88)             59 (35.12)     122 (57.55)    90 (42.45)     PCR-RFLP
  22                                                               D Cox et al \[[@B35-cancers-12-00471]\]                 2007                Caucasian           1,185               1651          469                         548                           168                     613         797                           241         1486 (62.7)             884 (37.3)     2023 (61.27)   1279 (38.73)   Taqman
  23                                                               Gonullu et al \[[@B36-cancers-12-00471]\]               2007                Turkey              38                  24            20                          10                            8                       11          9                             4           50 (65.8)               26 (34.2)      31 (64.58)     17 (35.42)     PCR
  24                                                               A Cox et al (GESBC) \[[@B37-cancers-12-00471]\]         2007                Caucasian           556                 713           169                         284                           103                     255         338                           120         622 (55.9)              490 (44.1)     848 (59.47)    578 (40.53)    Taqman
  25                                                               A Cox et al (HBCS) \[[@B37-cancers-12-00471]\]          2007                Caucasian           1,073               1013          386                         506                           181                     388         471                           154         1278 (59.55)            868 (40.45)    1247 (61.55)   779 (38.45)    Taqman
  26                                                               A Cox et al (IARC-Thai) \[[@B37-cancers-12-00471]\]     2007                Asian               453                 356           189                         213                           51                      161         162                           33          591 (65.23)             315 (34.77)    484 (67.98)    228 (32.02)    Taqman
  27                                                               A Cox et al (Kuopio) \[[@B37-cancers-12-00471]\]        2007                Caucasian           435                 442           229                         175                           31                      225         189                           28          633 (72.76)             237 (27.24)    639 (72.29)    245 (27.71)    Taqman
  28                                                               A Cox et al (Mayo Clinic) \[[@B37-cancers-12-00471]\]   2007                Caucasian           793                 837           296                         404                           93                      307         409                           121         996 (62.8)              590 (37.2)     1023 (61.1)    651 (38.89)    Taqman
  29                                                               A Cox et al (PBCS) \[[@B37-cancers-12-00471]\]          2007                Caucasian           1,841               2254          617                         890                           334                     797         1104                          353         2124 (57.67)            1558 (42.33)   2698 (59.85)   1810 (40.15)   Taqman
  30                                                               A Cox et al (SEARCH) \[[@B37-cancers-12-00471]\]        2007                Caucasian           4,504               5689          1670                        2138                          696                     2200        2716                          773         5478 (60.8)             3530 (39.2)    7116 (62.54)   4262 (37.46)   Taqman
  31                                                               A Cox et al (Seoul) \[[@B37-cancers-12-00471]\]         2007                Asian               643                 529           162                         327                           154                     155         253                           121         651 (50.62)             635 (49.38)    563 (53.21)    495 (46.79)    Taqman
  32                                                               A Cox et al (SASBAC) \[[@B37-cancers-12-00471]\]        2007                Caucasian           1,303               1494          539                         596                           168                     657         637                           200         1674 (64.2)             932 (35.8)     1951 (65.3)    1037 (34.7)    Taqman
  33                                                               A Cox et al (CNIO) \[[@B37-cancers-12-00471]\]          2007                Caucasian           640                 739           160                         313                           167                     217         355                           167         633 (49.45)             647 (50.55)    789 (53.38)    689 (46.62)    Taqman
  34                                                               A Cox et al (USRT) \[[@B37-cancers-12-00471]\]          2007                Caucasian           705                 1043          243                         339                           123                     382         494                           167         825 (58.51)             585 (41.49)    1258 (60.31)   828 (39.69)    Taqman
  35                                                               Rajkumar et al \[[@B38-cancers-12-00471]\]              2008                Asian               250                 500           80                          126                           44                      190         234                           76          286 (57.2)              214 (42.8)     614 (61.4)     386 (38.6)     PCR-CTPP
  36                                                               Joshi et al \[[@B39-cancers-12-00471]\]                 2011                Asian               203                 384           67                          104                           32                      114         181                           89          238 (58.62)             168 (41.38)    409 (53.25)    359 (46.75)    PCR-SSP
  37                                                               Zhang et al \[[@B40-cancers-12-00471]\]                 2011                Asian               170                 178           38                          76                            56                      49          79                            50          152 (44.7)              188 (55.3)     177 (49.72)    179 (50.28)    PCR-RFLP
  38                                                               Pooja et al \[[@B41-cancers-12-00471]\]                 2013                Asian               465                 239           85                          165                           214                     51          123                           64          335 (36.1)              593 (63.9)     225 (47.27)    251 (52.73)    PCR-seq
  39                                                               Eva et al \[[@B42-cancers-12-00471]\]                   2013                Caucasian           274                 252           99                          131                           44                      87          117                           48          329 (60.0)              219 (40)       291 (57.74)    213 (42.26)    Taqman
  40                                                               Amani et al \[[@B43-cancers-12-00471]\]                 2014                Iranian             100                 104           45                          28                            27                      33          41                            30          118 (59)                82 (41)        107 (51.44)    101 (48.56)    PCR-seq
  41                                                               Joshi et al \[[@B44-cancers-12-00471]\]                 2014                Asian               172                 229           60                          81                            31                      61          114                           54          201 (58.43)             143 (41.57)    236 (51.53)    222 (48.47)    PCR-SSP
  42                                                               Tezerjani et al \[[@B45-cancers-12-00471]\]             2015                Iranian             60                  60            18                          29                            13                      16          32                            12          65 (54.17)              55 (45.83)     64 (53.33)     56 (46.67)     PCR-ARMS
  **S.No**                                                         **First Author**                                        **Year**            **Ethnicity**       **Case**            **Control**   **Genotype Distribution**   **Allele Distribution (%)**   **Genotyping method**                                                                                                                              
                                                                   **TGFβ1 -509 C/T or -1349C\>T or rs1800469**            **Breast Cancer**   **Control**         **Breast Cancer**   **Control**                                                                                                                                                                                                                
                                                                                                                                                                                                     **CC**                      **CT**                        **TT**                  **CC**      **CT**                        **TT**      **C**                   **T**          **C**          **T**          
  1                                                                Dunning et al ^a^ \[[@B9-cancers-12-00471]\]            2003                UK                  2439                2366          1181                        1014                          244                     1194        977                           195         3376 (69.21)            1502 (30.79)   3365 (71.11)   1367 (28.89)   Taqman
  2                                                                Dunning et al ^b^ \[[@B9-cancers-12-00471]\]            2003                European            417                 634           159                         201                           57                      281         287                           66          519 (62.23)             315 (37.77)    849 (66.96)    419 (33.04)    Taqman
  3                                                                Dunning et al ^c^ \[[@B9-cancers-12-00471]\]            2003                Finnland            480                 452           277                         176                           27                      252         177                           23          730 (76.04)             230 (23.96)    681 (75.33)    223 (24.67)    Taqman
  4                                                                jin et al ^a^ \[[@B28-cancers-12-00471]\]               2004                Finnland            221                 320           133                         80                            8                       182         119                           19          346 (78.28)             96 (21.72)     483 (75.47)    157 (24.53)    PCR-RFLP, PCR-ALF
  5                                                                jin et al ^b^ \[[@B28-cancers-12-00471]\]               2004                Polish              170                 188           71                          81                            18                      74          95                            19          223 (65.59)             117 (34.41)    243 (64.63)    133 (35.37)    PCR-RFLP, PCR-ALF
  6                                                                Saha et al \[[@B29-cancers-12-00471]\]                  2004                Asian               26                  97            3                           22                            1                       35          53                            9           28 (53.85)              24 (46.15)     123 (63.4)     71 (36.6)      PCR-SSCP
  7                                                                Shin et al \[[@B30-cancers-12-00471]\]                  2005                Asian               1118                1206          260                         559                           299                     260         628                           318         1049 (48.26)            1157 (51.74)   1148 (47.6)    1264 (52.4)    PCR-RFLP
  8                                                                D Cox et al \[[@B35-cancers-12-00471]\]                 2007                Caucasian           1195                1663          600                         506                           89                      786         723                           154         1706 (71.38)            684 (28.62)    2295 (69)      1031 (31)      Taqman
  9                                                                Jakubowska et al \[[@B46-cancers-12-00471]\]            2009                Caucasian           1011                1068          454                         451                           106                     465         476                           127         1359 (67.21)            663 (32.79)    1406 (65.82)   730 (34.18)    PCR-RFLP
  10                                                               Jakubowska et al \[[@B47-cancers-12-00471]\]            2010                Caucasian           319                 290           127                         144                           48                      115         145                           30          398 (62.38)             240 (37.62)    375 (64.66)    205 (35.34)    PCR-RFLP
  11                                                               MARIE-GENICA \[[@B48-cancers-12-00471]\]                2010                Caucasian           3146                5485          1529                        1315                          302                     2616        2313                          556         4373 (69.5)             1919 (30.5)    7545 (68.78)   3425 (31.22)   MALDI-TOF Msa and PCR-RFLP
  12                                                               Babyshkina et al \[[@B49-cancers-12-00471]\]            2011                Russian             218                 290           89                          108                           21                      103         133                           54          286 (65.6)              150 (34.4)     339 (58.45)    241 (41.55)    PCR-RFLP
  13                                                               Zhang et al \[[@B40-cancers-12-00471]\]                 2011                Asian               170                 178           28                          93                            49                      41          84                            53          149 (43.82)             191 (56.18)    166 (46.63)    190 (53.37)    PCR-RFLP
  14                                                               Quan et al ^a^ \[[@B50-cancers-12-00471]\]              2013                Afro-American       454                 405           268                         164                           22                      215         165                           25          700 (77.09)             208 (22.91)    595 (73.46)    215 (26.54)    MassArray IPLEX Gold Assay
  15                                                               Quan et al ^b^ \[[@B50-cancers-12-00471]\]              2013                European            327                 312           124                         147                           56                      134         135                           43          395 (60.4)              259 (39.6)     403 (64.58)    221 (35.42)    MassArray IPLEX Gold Assay
  16                                                               Vinod et al \[[@B51-cancers-12-00471]\]                 2013                Asian               153                 128           64                          66                            23                      70          36                            22          194 (63.4)              112 (36.6)     176 (68.75)    80 (31.25)     PCR-ARMS
  17                                                               Parvizi et al \[[@B52-cancers-12-00471]\]               2016                Iranian             100                 100           31                          50                            19                      21          48                            31          112 (56)                88 (44)        90 (45)        110 (55)       PCR-RFLP
  **S.No**                                                         **First Author**                                        **Year**            **Ethinic group**   **Case**            **Control**   **Genotype Distribution**   **Allele Distribution (%)**   **Genotyping method**                                                                                                                              
                                                                   **TGFβ1\* 6A or rs11466445**                                                                    **Case**            **Control**   **Case**                    **Control**                                                                                                                                                                      
                                                                                                                                                                                                     **9A/9A**                   **9A/6A**                     **6A/6A**               **9A/9A**   **9A/6A**                     **6A/6A**   **9A**                  **6A**         **9A**         **6A**         
  1                                                                Pasche et al \[[@B19-cancers-12-00471]\]                1999                USA                 152                 732           128                         24                            0                       654         78                            0           280 (92.11)             24 (7.89)      1386 (94.67)   78 (5.33)      PCR-RFLP
  2                                                                Baxter et al \[[@B21-cancers-12-00471]\]                2002                United Kingdom      355                 248           268                         83                            4                       207         39                            2           619 (87.18)             91 (12.82)     453 (91.33)    43 (8.67)      PCR-SSCP
  3                                                                Reiss et al \[[@B53-cancers-12-00471]\]                 2004                USA                 98                  91            87                          11                            0                       77          14                            0           185 (94.39)             11 (5.61)      168 (92.31)    14 (7.69)      PCR-RFLP
  4                                                                Caldes et al \[[@B53-cancers-12-00471]\]                2004                USA                 506                 292           397                         106                           3                       250         42                            0           900 (88.93)             112 (11.07)    542 (92.81)    42 (7.19)      PCR-RFLP
  5                                                                Offit et al \[[@B53-cancers-12-00471]\]                 2004                USA                 462                 330           391                         67                            4                       291         38                            1           849 (91.88)             75 (8.12)      620 (93.94)    40 (6.06)      PCR-RFLP
  6                                                                jin et al ^a^ \[[@B28-cancers-12-00471]\]               2004                Finnish             221                 234           177                         38                            6                       171         60                            3           392 (88.69)             50 (11.31)     402 (85.9)     66 (14.1)      PCR-RFLP
  7                                                                jin et al ^b^ \[[@B28-cancers-12-00471]\]               2004                Polish              170                 202           140                         28                            2                       176         26                            0           308 (90.59)             32 (9.41)      378 (93.56)    26 (6.44)      PCR-RFLP
  8                                                                Kaklamani et al \[[@B31-cancers-12-00471]\]             2005                USA                 611                 690           515                         92                            4                       612         77                            1           1122 (91.82)            100 (8.18)     1301 (94.28)   79 (5.72)      PCR-seq
  9                                                                Chen et al \[[@B54-cancers-12-00471]\]                  2006                USA                 115                 130           92                          23                            0                       111         18                            1           207 (90)                23 (10)        240 (92.31)    20 (7.69)      PCR-SSCP
  10                                                               Figelson et al \[[@B33-cancers-12-00471]\]              2006                USA                 387                 384           387                                                                               384                                                                                                                        PCR
  11                                                               D Cox et al \[[@B35-cancers-12-00471]\]                 2007                USA                 1,187               1673          968                         207                           12                      1352        302                           19          2143 (90.27)            231 (9.73)     3006 (89.84)   340 (10.16)    Taqman
  12                                                               Song et al \[[@B55-cancers-12-00471]\]                  2007                Sweden              763                 852           598                         152                           13                      682         160                           10          1348 (88.34)            178 (11.66)    1524 (89.44)   180 (10.56)    PCR
  13                                                               Colleran et al \[[@B56-cancers-12-00471]\]              2010                Ireland             960                 958           796                         154                           10                      785         160                           13          1746 (90.94)            174 (9.06)     1730 (90.29)   186 (9.71)     PCR
  14                                                               Jakubowska et al \[[@B47-cancers-12-00471]\]            2010                Poland              282                 252           282                                                                               252                                                                                                                        PCR-RFLP
  15                                                               Joshi et al \[[@B39-cancers-12-00471]\]                 2011                Asian               209                 391           196                         12                            1                       361         28                            2           404 (96.65)             14 (3.35)      750 (95.91)    782 (4.09)     PCR-SSP
  16                                                               kamali et al \[[@B57-cancers-12-00471]\]                2015                Iranian             280                 280           251                         25                            4                       241         27                            12          525 (94.09)             33 (5.91)      509 (90.89)    560 (9.11)     PCR
  ---------------------------------------------------------------- ------------------------------------------------------- ------------------- ------------------- ------------------- ------------- --------------------------- ----------------------------- ----------------------- ----------- ----------------------------- ----------- ----------------------- -------------- -------------- -------------- ----------------------------

Dunning et al. UK population designated as ^(a)^, European ethnic group designated as ^(b)^, and Finland population designated as ^(c)^. Marchand et al. African-American ethnic group designated as ^(a)^, Latinos designated as ^(b)^, Whites designated as ^(c)^, Japanese designated as ^(d)^, and Hawaiian designated as ^(e)^. Jin et al. Finland population designated as ^(a)^, Polish designated as ^(b)^, German designated as ^(c)^, and Swedish designated as ^(d)^. Quin et al. African-American ethnic group designated as ^(a)^ and European designated as ^(b)^.
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###### 

Stratified analysis of TGFβ polymorphisms and their association with BC risk.

                                                                      Model                               Odds Ratio (OR)   95% CI         *p*-Value
  ------------------------------------------------------------------- ----------------------------------- ----------------- -------------- -----------
  ***TGF-β1* 29C\>T (Pro10Leu) or T869C or rs1982073 or rs1800470**                                                                        
  **Caucasian**                                                                                                                            
  1                                                                   Overall allele C vs. T              1.008             0.961--1.057   0.749
  2                                                                   Homozygous CC vs. TT                1.007             0.907--1.120   0.891
  3                                                                   Heterozygous TC vs. TT              1.038             0.990--1.088   0.123
  4                                                                   Recessive CC vs. TT + TC            0.997             0.910--1.093   0.947
  5                                                                   Dominant CC + TC vs. TT             1.039             0.994--1.086   0.093
  **Asian**                                                                                                                                
  6                                                                   Overall allele C vs. T              1.058             0.952--1.176   0.298
  7                                                                   Homozygous CC vs. TT                1.084             0.894--1.314   0.413
  8                                                                   Heterozygous TC vs. TT              1.115             1.006--1.237   0.039
  9                                                                   Recessive CC vs. TT + TC            1.055             0.875--1.271   0.576
  10                                                                  Dominant CC + TC vs. TT             1.077             0.980--1.182   0.123
  **European**                                                                                                                             
  11                                                                  Overall allele C vs. T              1.142             0.761--1.715   0.521
  12                                                                  Homozygous CC vs. TT                1.466             0.516--4.116   0.473
  13                                                                  Heterozygous TC vs. TT              1.319             0.536--3.247   0.547
  14                                                                  Recessive CC vs. TT + TC            1.227             0.882--1.707   0.224
  15                                                                  Dominant CC + TC vs. TT             1.355             0.552--3.312   0.505
  **Middle Eastern**                                                                                                                       
  16                                                                  Overall allele C vs. T              0.833             0.625--1.110   0.212
  17                                                                  Homozygous CC vs. TT                0.784             0.461--1.332   0.367
  18                                                                  Heterozygous TC vs. TT              0.602             0.375--0.966   0.035
  19                                                                  Recessive CC vs. TT + TC            1.011             0.632--1.618   0.964
  20                                                                  Dominant CC + TC vs. TT             0.669             0.438--1.020   0.062
  ***TGFβ-1*-509 C/T or -1349C\>T or rs1800469**                                                                                           
  **Caucasian**                                                                                                                            
  21                                                                  Overall allele T vs. C              0.953             0.905--1.004   0.068
  22                                                                  Homozygous TT vs. CC                0.904             0.803--1.018   0.096
  23                                                                  Heterozygous CT vs. CC              0.957             0.891--1.028   0.228
  24                                                                  Recessive TT vs. CC + CT            0.924             0.825--1.036   0.175
  25                                                                  Dominant TT + CT vs. CC             0.947             0.885--1.031   0.112
  **European**                                                                                                                             
  26                                                                  Overall allele T vs. C              1.016             0.900--1.148   0.795
  27                                                                  Homozygous TT vs. CC                1.039             0.770--1.401   0.804
  28                                                                  Heterozygous CT vs. CC              1.038             0.950--1.135   0.405
  29                                                                  Recessive TT vs. CC + CT            1.026             0.782--1.346   0.853
  30                                                                  Dominant TT + CT vs. CC             1.058             0.972--1.151   0.190
  **Asian**                                                                                                                                
  31                                                                  Overall allele T vs. C              1.023             0.925--1.132   0.657
  32                                                                  Homozygous TT vs. CC                1.000             0.813--1.230   0.990
  33                                                                  Heterozygous CT vs. CC              1.633             0.894--2.986   0.111
  34                                                                  Recessive TT vs. CC + CT            0.993             0.842--1.171   0.936
  35                                                                  Dominant TT + CT vs. CC             1.460             0.886--2.408   0.138
  ***TGF-β* \*6A or rs11466445**                                                                                                           
  **European**                                                                                                                             
  36                                                                  Overall allele 6A vs. 9A            1.095             0.878--1.364   0.421
  37                                                                  Homozygous 6A/6A vs. 9A/9A          1.247             0.749--2.075   0.396
  38                                                                  Heterozygous 6A/9A vs. 9A/9A        1.056             0.809--1.378   0.690
  39                                                                  Recessive 6A/6A vs. 9A/9A + 9A/6A   1.249             0.751--2.077   0.391
  40                                                                  Dominant 6A/6A + 9A/6A vs. 9A/9A    1.049             0.839--1.311   0.675

[^1]: Running Title: *TGF-β1* polymorphism in breast cancer.
